[Form 4] ABBOTT LABORATORIES Insider Trading Activity

ABBOTT LABORATORIES Executive Vice President Mary K. Moreland reported insider share transactions.

Rhea-AI Filing Summary

ABBOTT LABORATORIES Executive Vice President Mary K. Moreland reported insider share transactions. On March 2, 2026, she completed an open-market sale of 613 common shares at $115.58 per share. On February 27, 2026, 4,630 common shares were disposed of at $116.26 per share to cover tax liabilities by delivering shares.

After these transactions, her directly held common shares totaled 104,291. In addition, 11,845 common shares were held indirectly through a Profit Sharing Trust, with that trust balance reported as of February 27, 2026.

Insider Trade Summary

Net Seller: 613 shares

Net Sell 3 txns

Insider Moreland Mary K

Role EXECUTIVE VICE PRESIDENT

Sold 613 shs ($71K)

Type	Security	Shares	Price	Value
Sale	Common shares without par value	613	$115.58	$71K
Exercise Price or Tax Liability	Common shares without par value	4,630	$116.26	$538K
holding	Common shares without par value	--	--	--

Holdings After Transaction: Common shares without par value — 104,291 shares (Direct); Common shares without par value — 11,845 shares (Indirect, Profit Sharing Trust)

Footnotes (1)

1. F1. Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2026.

FAQ

What insider transactions did ABBOTT LABORATORIES (ABT) report for Mary K. Moreland?

ABBOTT LABORATORIES reported that Executive Vice President Mary K. Moreland sold 613 common shares in an open-market transaction and disposed of 4,630 shares to cover tax liabilities. These Form 4 disclosures detail her recent trading and share-based tax withholding activity.

How many ABBOTT LABORATORIES (ABT) shares did Mary K. Moreland sell in the open market?

Mary K. Moreland sold 613 ABBOTT LABORATORIES common shares in an open-market transaction at $115.58 per share. This sale is reported as a non-derivative transaction and reflects a relatively small portion of her overall directly held share position.

Why were 4,630 ABBOTT LABORATORIES (ABT) shares disposed of for Mary K. Moreland?

The 4,630 ABBOTT LABORATORIES common shares were disposed of to satisfy tax liabilities by delivering shares, at a reported price of $116.26 per share. This tax-withholding disposition is a common mechanism when equity awards vest or are exercised.

How many ABBOTT LABORATORIES (ABT) shares does Mary K. Moreland hold after these transactions?

After the reported transactions, Mary K. Moreland directly owned 104,291 ABBOTT LABORATORIES common shares. She also had an additional 11,845 common shares held indirectly through a Profit Sharing Trust, with that trust balance stated as of February 27, 2026.

What is the nature of Mary K. Moreland’s indirect ABBOTT LABORATORIES (ABT) share ownership?

Mary K. Moreland’s indirect ABBOTT LABORATORIES ownership is through a Profit Sharing Trust, identified as the Abbott Laboratories Stock Retirement Trust. The filing notes a balance of 11,845 common shares in this trust as of February 27, 2026, separate from her directly held shares.

What do the Form 4 codes S and F mean in ABBOTT LABORATORIES (ABT) filing?

Code S indicates an open-market or private sale of ABBOTT LABORATORIES shares, used for the 613-share transaction. Code F indicates shares delivered to pay an exercise price or tax liability, used for the 4,630-share tax-withholding disposition reported for Mary K. Moreland.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moreland Mary K

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXECUTIVE VICE PRESIDENT

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/27/2026		F		4,630	D	$116.26	104,904	D
Common shares without par value	03/02/2026		S		613	D	$115.58	104,291	D
Common shares without par value								11,845(1)	I	Profit Sharing Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2026.

	/s/ Mary K. Moreland by Jessica H. Paik, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.